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ABSTRACT 16 
Amphiphilic derivatives of poly(benzyl malate) were synthesized and characterized with the aim of 17 
being used as degradable and biocompatible building blocks for the design of functional nanoparticles 18 
(NPs). An anti-cancer model drug, doxorubicin, has been successfully encapsulated into the prepared 19 
NPs and its release profile has been evaluated in water and in culture medium. NPs bearing biotin 20 
molecules were prepared either for site-specific drug delivery via the targeting of biotin receptors 21 
overexpressed on the surface of several cancer cells, or for grafting biotinylated cyclic RGD peptide 22 
onto their surface using the strong and highly specific interactions between biotin and the streptavidin 23 
protein. We have shown that this binding did not affect dramatically the physico-chemical properties 24 
of the corresponding NPs. Cyclic RGD grafted fluorescent NPs were more efficiently uptaken by the 25 
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HepaRG hepatoma cells than biotinylated fluorescent NPs. Furthermore, the targeting of HepaRG 26 
hepatoma cells with NPs bearing cyclic RGD was very efficient and much weaker for HeLa and HT29 27 
cell lines confirming that cyclic RGD is a suitable targeting agent for liver cells. Our results also 28 
provide a new mean for rapid screening of short hepatotropic peptides in order to design NPs showing 29 
specific liver targeting properties. 30 
 31 
1. Introduction 32 
Nanotechnology, especially nanomedicine corresponding to the use of nanoparticles (NPs) in 33 
biomedicine, is currently an ever growing scientific and technological domain [Psimidas et al., 2012; 34 
Garanger et al., 2012]. The main reason for this unprecedented development relies on the aim to 35 
improve both early detection and treatment of numerous pathologies such as cancers. The 36 
encapsulation of a selected biologically active molecule into NPs might result in an increased drug 37 
bioavaibility within solid tumors, arising from a decrease in its non-specific recognition by the 38 
reticuloendothelial system (RES) and an improvement of its in vivo specific biodistribution, as well as 39 
a minimized toxicity against healthy tissues and organs [Yan et al., 2012; Elsaesser et al., 2012; 40 
Lamprecht, 2008]. Knowing that cancer, characterized by an abnormal and anarchical cell proliferation 41 
within normal tissue, is a very complex disease and a major cause of mortality [Misra et al., 2010], the 42 
development of efficient nanomedicine is thus a major challenge for public health [Reddy et al., 2011]. 43 
In this context, several anti-cancer drug loaded NPs  such as Doxyl® and Abraxane® have been 44 
approved by the Food and Drug Administration (FDA) for clinical uses [Yan et al., 2012; Wang et al., 45 
2012; Jain et al., 2010]. However besides these encouraging results, several challenges have to be 46 
overcome in order to obtain NPs allowing highly efficient site-specific drug delivery. 47 
 The materials constituting the NPs have to respect very strict specifications: they must be (i) 48 
biocompatible and non-toxic, (ii) (bio)degradable into non-toxic low molecular weight molecules or, at 49 
least, bioassimilable after releasing the encapsulated drug, (iii) undetectable by the RES meaning 50 
having stealth properties, (iv) adapted for carrying large amounts of drug that should be released in a 51 
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controlled manner at its site of action (targeting). Within this context, we have recently developed a 52 
family of degradable non-toxic polymers derived from poly(malic acid), PMLA, which are able to 53 
form well-defined NPs [Huang et al., 2012]. We have selected PMLA as macromolecular backbone 54 
because this polymer, originally synthesized for application in the biomedical field, has been 55 
successfully used as a platform in the synthesis of nanovectors [Huang et al., 2012; Cammas et al., 56 
2000; Cammas-Marion et al., 2000; Osanai et al., 2000; Martinez Barbosa et al., 2004; Abdellaoui et 57 
al., 1998] and macromolecular conjugates [Ding et al., 2010; Ljubimova et al., 2008; Fujita et al., 58 
2007; Fujita et al., 2006]. PMLA is known to be non-toxic and degradable into malic acid under 59 
physiological conditions [Vert et al., 1979] and its derivatives are accessible from naturally occurring 60 
PMLA [Ljubimova et al., 2008] or by anionic ring-opening polymerization (ROP) of β-substituted β-61 
lactones [Cammas et al., 1996; Cammas et al., 1993]. PMLA derivatives used for the formulation of 62 
NPs were obtained by ROP of benzyl malolactonate (MLABe) in presence of either 63 
tetraethylammonium benzoate, α-methoxy ω-carboxy poly(ethylene glycol) -PEG42-CO2H- or α-biotin 64 
ω-carboxy poly(ethylene glycol) -Biot-PEG62-CO2H- as initiator [Huang et al., 2012]. Starting from 65 
these three PMLA derivatives, we were able to obtain well-defined non-toxic NPs in which the 66 
doxorubicin (Dox), and a fluorescent probe, the DiD oil, have been successfully encapsulated for in 67 
vitro assays [Huang et al., 2012]. It is worth noting that PEG has been selected as hydrophilic block 68 
because it is a well-known polymer conferring stealth properties at nanoparticles on which it is grafted 69 
[Romberg et al., 2008].  On the other hand, biotin has been chosen firstly because it is a targeting agent 70 
of certain cancer cells [Le Droumaguet et al., 2012; Patil et al., 2099; Kim et al., 2007] and secondly 71 
because it is able to interact strongly with streptavidin [Yang et al., 2009] which is an important 72 
property for our study as it will be explained afterwards in this paper. 73 
Hepatocellular carcinoma (HCC) is the main primary malignant tumor of the liver representing 80 to 74 
90% of liver tumors. It is the fifth most common tumor worldwide (5.4% of new cancer cases per year) 75 
and the third in term of mortality (8.2% of all cancer death) [Parkin et al., 2005]. Early detection and 76 
classification of HCC are crucial for the choice and effectiveness of therapeutic strategy. For small size 77 
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HCC, surgical treatment (resection and liver transplantation) is the most effective treatment [Hasegawa 78 
et al., 2009; Mazzeferro et al., 2008; Ishikawa et al., 1992]. Palliative treatments such as 79 
chemoembolization [Bernades-Genisson et al., 2003] and, more recently, chemotherapy using an 80 
inhibitor of tyrosine kinase, Sorafenib (Nexavar®) are proposed to patients with advanced HCC. 81 
Despites these advances, the therapeutic options for the treatment of HCC remains limited partly due 82 
to the chemoresistance of liver tumors to conventional anti-tumor agents. Therefore, the use of 83 
nanocarriers containing anti-tumor drugs has been envisaged for the treatment of HCC in order to 84 
increase the intra-hepatic drug concentration while limiting the exposure of healthy tissues and side 85 
effects [Reddy et al., 2011]. Several formulations are currently undergoing clinical trials in phase II 86 
and III such as NPs of poly(alkyl cyanoacrylate) loaded with doxorubicin (Trandrug®) for HCC 87 
treatment [Barraud et al., 2005]. In a first step, the passive accumulation of nanocarriers in the RES 88 
cells (endothelial and Kupffer cells) [Lanaerts et al., 1984] was utilized for liver targeting with a real 89 
relevance for diseases involving liver Kupffer cells such as parasitic diseases [Alving et al., 1978]. 90 
Conversely, liver targeting based on the nanocarrier’s uptake by Kupffer cells has the major drawback 91 
of allowing only a low hepatic accumulation of nanocarriers since Kupffer cells represent only a few 92 
percent of liver cell volume against 90% for hepatocytes. In addition, the accumulation of nanocarriers 93 
in Kupffer cells does not target the cells responsible for HCC thus limiting the use of this approach in 94 
this case. Therefore, to overcome this drawback, active hepatocyte targeting has been studied. Most of 95 
the proposed strategies are based on the binding of NPs to the asialoglycoprotein receptors [Wu et al., 96 
2002]. These NPs are usually liposomes incorporating glycosylated proteins or galactose/lactose linked 97 
to lipophilic anchors [Wu et al., 2002]. To date, very few nanovectors, especially polymer-based NPs, 98 
carrying peptides with high tropism for the liver have been developed [Reddy et al., 2011]. 99 
 In this paper, we report, first, the monitoring of Dox release from NPs prepared from PEG42-b-100 
PMLABe or Biot-PEG62-b-PMLABe in water and in culture medium at 37°C. Second, we have grafted 101 
fluorescein amine (FA) molecule at the free end of the PMLABe block of PEG42-b-PMLABe or Biot-102 
PEG62-b-PMLABe block copolymers in order to obtain fluorescent NPs for in vitro cell uptake assays. 103 
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Starting from the corresponding fluorescent NPs, we have studied the influence of the nature of 104 
molecules localized at NPs’ surfaces [PEG42, Biot-PEG62 or Arginine-Glycine-Aspartic acid (RGD) 105 
peptide-Biot-Streptavidin-Biot-PEG62] on their internalization into cells in vitro and demonstrated that 106 
the uptake by HepaRG hepatoma cells is considerably enhanced by the grafting of the RGD peptide 107 
onto NPs. These results also show that these biotinylated NPs can be useful tools for rapid in vitro 108 
screen and selection of highly hepatotropic peptides with the ultimate goal to design nanomedicine 109 
targeting hepatocytes from HCC in vivo.   110 
 111 
2. Materials and methods 112 
2.1. Materials 113 
All chemicals were used as received. Anhydrous THF was obtained by distillation over 114 
sodium/benzophenone under N2 atmosphere. 115 
Three cell lines have been selected within the frame of this project: the HepaRG hepatoma cells 116 
[Gripon at al., 2002; Laurent et al., 2010;], the colorectal adenocarcinoma cell line HT29 [Fogh et al., 117 
1975] and the cervical cancer cell line HeLa [Rahbari et al., 2009].  118 
 119 
2.2. Apparatus 120 
Nuclear magnetic resonance spectra (1H NMR) were recorded on a Brucker ARX 400 instrument (1H 121 
at 400 MHz). Data are reported as follows: chemical shift (multiplicity, number of hydrogen). The 122 
chemical shifts (δ) are reported as parts per million (ppm) referenced to the appropriate residual solvent 123 
peak. Abbreviations are as follows: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of 124 
doublet), m (multiplet). 125 
The size (average diameter obtained by the cumulant result method), polydispersity and zeta potential 126 
of the formulations were measured by dynamic light scattering using a Delsa™ Nano Beckman 127 
Coulter apparatus at 25°C. 128 
UV spectra were recorded on a Secoman apparatus at 485 nm. 129 
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2.3. Synthesis of PEG42-b-PMLABe and Biot-PEG62-b-PMLABe  130 
The monomer, the benzyl malolactonate (MLABe), was synthesized from DL-aspartic acid according 131 
to the previously reported synthesis [Cammas et al., 1996]. The PEG42-b-PMLABe and Biot-PEG62-b-132 
PMLABe block copolymers were obtained by anionic ring opening polymerization of MLABe in 133 
presence of, respectively, α-methoxy ω-carboxy poly(ethylene glycol), PEG42-CO2H, and  α-biotin ω-134 
carboxy poly(ethylene glycol), Biot-PEG62-CO2H, as initiators following a protocol described 135 
elsewhere [Huang et al., 2012]. 136 
 137 
2.4. Grafting of fluorescein amine (FA) 138 
 2.4.1 Grafting of FA on the PEG42-b-PMLABe block copolymer (Scheme 1) 139 
The PEG42-b-PMLABe block copolymer (500 mg) was dissolved into 1 mL of anhydrous CH2Cl2 140 
under nitrogen atmosphere. To this solution were added 5 mg (1eq.) of N,N’-diclohexylcarbodiimide 141 
(DCC) dissolved in 1 mL of anhydrous CH2Cl2 followed by 7.5 mg (1eq.) of N-hydroxysuccinimide 142 
(NSH) dissolved in 1 mL of anhydrous CH2Cl2. The mixture was stirred under nitrogen atmosphere for 143 
24 hours at room temperature (RT). The resulting PEG42-b-PMLABe-NHS was precipitated in cold 144 
heptane. After the elimination of the supernatant, the precipitate was dissolved in CH2Cl2 and the 145 
solution was filtrated on celite. The CH2Cl2 was eliminated under vacuum and the activated block 146 
copolymer polymer (480 mg) was obtained with 96% yield. The activated block copolymer (480 mg) 147 
was then dissolved in 1 mL of anhydrous CH2Cl2. To this solution was added 12 mg of FA (1eq.) 148 
solubilised into a mixture of 1 mL of anhydrous CH2Cl2 and 1 mL of acetone HPLC grade under 149 
nitrogen atmosphere. After stirring at RT for 24 hours, the solution containing the PEG42-b-PMLABe-150 
FA block copolymer was precipitated into cold heptane. After removing the supernatant, the 151 
precipitate was dissolved into DMSO. This DMSO solution was poured into a dialysis bag (MWCO 152 
3,500 Da) and the dialysis was conducted during 8 hours against DMSO. The solution contained into 153 
the dialysis bag was lyophilized and the PEG42-b-PMLABe-FA block copolymer was recovered with 154 
60% yield. The polymer was characterized by 1H NMR in deuterated DMSO. 155 
 7 
 
1H NMR (d6-DMSO, δ ppm): 2.92 (s, 2nH, CO2CH2C6H5), 3.32 (m, 4mH (m=42), (CH2CH2O)42), 5.10 156 
(m, 2nH, CHCH2CO2), 5.42 (m, 1nH, CHCH2CO2), 6.50-7.00 (m, 9H, FA); 7.31 (m, 5nH, 157 
CO2CH2C6H5). 158 
MNMR = 11,000 g/mol for the PMLABe block 159 
  160 
 2.4.2 Grafting of FA on the Biot-PEG62-b-PMLABe block copolymer (Scheme 1) 161 
The grafting of FA on the Biot-PEG62-b-PMLABe block copolymer was realized as described above. 162 
The Biot-PEG62-b-PMLABe-FA block copolymer was obtained with 58% yield and characterized by 163 
1H NMR in DMSO. 164 
1H NMR (d6-DMSO, δ ppm): 2.92 (s, 2nH, CO2CH2C6H5), 3.37 (m, 4mH (m=62), (CH2CH2O)62), 5.07 165 
(m, 2nH, CHCH2CO2), 5.41 (m, 1nH, CHCH2CO2), 6.50-7.00 (m, 9H, FA); 7.26 (m, 5nH, 166 
CO2CH2C6H5). Peaks corresponding to the biotin are either under peaks correspoonding to the PEG 167 
and PMLABe blocks or too small to be detectable on the NMR spectrum. 168 
MNMR = 6,000 g/mol for the PMLABe block. 169 
 170 
2.5. Preparation of NPs 171 
 2.5.1. Dox encapsulation and release from NPs  172 
The protocol for Dox encapsulation and for the monitoring of its release was the same whatever the 173 
nature of the block copolymer constituted the NPs. The encapsulation of Dox into the NPs was realised 174 
as described previously [Huang et al., 2012]. Briefly, the Dox hydrochloride (Dox,HCl, Sigma) was 175 
encapsulated into the two kinds of NPs during the nanoprecipitation procedure. The selected polymer 176 
(5 mg) was dissolved in acetone (1 mL). Two hundred µL of a Dox solution [1.5 mg of Dox,HCl 177 
solubilised in 0.6 mL of a mixture of chloroform (6 mL) and NEt3 (23 µL)] were added to the polymer 178 
solution. This mixture was then nanoprecipitated into 2 mL of water under vigorous stirring. After 179 
organic solvent evaporation, the unloaded Dox was removed by ultracentrifugation at 15,000 g at 15°C 180 
for 7 min using filter with an exclusion limit 10,000 Da. The filters were returned and centrifuged for 1 181 
 8 
 
min at 1,000 g at 15°C. The volume of the recovered solutions was completed to 2 mL with distilled 182 
water in order to obtain a final concentration in NPs of 2.5 g/L. The concentration of loaded Dox was 183 
evaluated by UV at 485 nm, as described elsewhere [Huang et al., 2012; Cammas et al., 1995]. Briefly, 184 
200 µL of Dox-loaded NPs were dissolved into 800 µL of DMF and the resulting solutions were 185 
analyzed by UV at 485 nm. The absorbance of Dox encapsulated into NPs was converted into a 186 
concentration using a calibration curve and the encapsulation efficiency (e.e.) was calculated using the 187 
following equation:  188 
 189 
 190 
The characteristics of the Dox-loaded NPs (diameter, polydispersity index and zeta potential) were 191 
measured using the Delsa™ Nano Beckman Coulter apparatus (Table 1). 192 
The Dox release from both kinds of NPs were monitoring by dialysis in water and in culture medium 193 
at 37°C. The protocol used in both cases was identical. Two mL of the Dox-loaded NPs solution were 194 
placed into a dialysis bag (MWCO = 3,500 Da); this bag was then incubated into 40 mL of water or 195 
culture medium maintained at 37°C. After different incubation time, from 30 min up to 72 hours, 2 mL 196 
of the outside solution are taken and replaced by 2 mL of fresh water or culture medium. For each 197 
sample, 200 µL of the collected outside solution were analyzed by UV at 485 nm and the quantity of 198 
Dox was determined thanks to calibration curves previously realized in water and in culture medium 199 
by UV measurements at 485 nm. 200 
 201 
 2.5.2. Preparation of fluorescent NPs 202 
The fluorescent NPs were prepared by the nanoprecipitation technique as previously described 203 
[Thioune et al., 1997; Huang et al., 2012]. Briefly, the mixture of PEG42-b-PMLABe-FA (2.5 mg) and 204 
PEG42-b-PMLABe (2.5 mg) or Biot-PEG62-b-PMLABe-FA (2.5 mg) and Biot-PEG62-b-PMLABe (2.5 205 
mg) were dissolved in 1 mL of acetone. This solution is added to 2 mL of water under vigorous 206 
stirring. The organic solvent (acetone) was then evaporated under vacuum and the final volume was 207 
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completed to 2 mL with fresh water. The final concentration in block copolymers under NPs’ form was 208 
2.5 g/L. The solutions containing the fluorescent NPs were characterized by dynamic light scattering 209 
using a Delsa™ Nano Beckman Coulter apparatus at 25°C (Table 2). 210 
 211 
 2.5.3. Grafting of the cyclic RGD peptide 212 
The selected biotinylated peptide, the cyclic Biot-RGD peptide (Eurogentec, Belgium), was grafted 213 
onto the biotinylated NP’s surfaces via the streptavidin (Strept, AnaSpect, Eurogentec, Belgium) 214 
protein. An aqueous solution of Biot-RGD peptide was prepared at a final concentration of 2.9 mM. In 215 
parallel, an aqueous solution of streptavidin was also prepared with a final concentration of 178 µM. 216 
The Biot-RGD peptide (2.7 µL) and the streptavidin (22 µL) solutions were mixed in a final volume of 217 
50 µL (H2O qsp) and incubated for 1 hour at 4°C. Then, the Biot-PEG62-b-PMLABe-FA or Biot-218 
PEG62-b-PMLABe based NP’s solution (35 µL), previously prepared, was added to a final volume of 219 
100 µL (H2O qsp). This mixture was incubated for 1 hour and diluted to a final volume of 1 mL in 220 
culture medium for final concentrations of the Biot-RGD peptide at 8µM, the streptavidin at 4µM and 221 
polymers at 4µM. In order to demonstrate that both the Biot-RGD peptide grafting and the dilution 222 
have no influence on NP’s characteristics, we analyzed the NPs formed in the conditions described 223 
above by DLS (Table 3). 224 
 225 
2.6. Cell uptake assays 226 
The cell lines, HT29 [Fogh et al., 1975] and HeLa [Rahbari et al., 2009], were cultured as described in 227 
the literature. The HepaRG cell line was cultured in the medium William’s E (Lonza) supplemented 228 
with 2mM of glutamine (Gibco), 5 mg/L of insulin (Sigma), 10-5 M hydrocortisone hemisuccinate and 229 
10% of fetal calf serum (Lonza) [Gripon at al., 2002; Laurent et al., 2010]. During the sub-culturing, 230 
2.106 cells were seeded in a 75 cm3 flask. The medium was renewed every 48 hours. The sub-culturing 231 
was realized by trypsinization every 2 weeks in order to maintain the progenitor phenotype. For an 232 
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optimal differentiation, the cells were maintained at confluence after the two weeks and the medium 233 
was supplemented with 2% of dimethylsulfoxide (DMSO) [Laurent et al., 2013].  234 
For the cell uptake assays, the 24 wells culture plates were seeded with the selected cell line (HepaRG, 235 
HT29 or HeLa) with 105 cells per well. Then the NPs’ preparations (4µM of block copolymer under 236 
NPs’ form ± 4 µM streptavidin and 8 µM Biot-RGD) or a negative control (buffer without NPs or non 237 
fluorescent NPs) were added to the wells. For the competitive experiments, the cells were pre-treated 238 
with an excess of free RGD peptide (32 µM). 239 
The cells were incubated from 1 to 24 hours. After incubation, the culture medium was removed; the 240 
cell monolayers were washed with PBS before the observation by fluorescence microscopy (Zeiss 241 
inverted microscope, analysis software AxioVision). Then the cells were detached with trypsin and 242 
analyzed by flow cytometry (FACSCalibur Becton Dikinson) to quantify the fluorescence (Channel 243 
FL1H) emitted by the fluorescent NPs captured by the cells. Cytometry data were analyzed using 244 
CellQuest software (Becton Dikinson). 245 
 246 
3. Results and Discussion 247 
In order to further characterize the PMLABe based NPs as drug nanocarriers for applications in 248 
nanomedicine, we (i) studied the release of Dox in water and culture medium at 37°C, (ii) grafted a 249 
fluorescent probe at the free end of the hydrophobic PMLABe block for studying in vitro cellular 250 
uptake and (iii) evaluated the possibility to build a molecular scaffold by grafting the cyclic RGD-251 
biotinylated peptide onto biotinylated NPs via the streptavidin as a bridging factor and determine the 252 
impact of the RGD peptide addition on cell uptake. 253 
 254 
Figure 1 255 
 256 
 257 
 258 
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3.1. Dox encapsulation and release from NPs  259 
Both Dox-loaded PEG42-b-PMLABe and Biot-PEG62-b-PMLABe based NPs have been prepared by 260 
the nanoprecipitation technique and have been characterized by DLS. Table 1 collects the results 261 
obtained for PEG42-b-PMLABe and Biot-PEG62-b-PMLABe based NPs. Initial Dox content in both 262 
NPs determined by UV at 485 nm as described previously [Huang et al., 2012] showed an 263 
encapsulation efficiency ranging from 32 to 36%. 264 
 265 
Table 1 266 
 267 
The release of Dox from both PEG42-b-PMLABe and Biot-PEG62-b-PMLABe NPs in water and in 268 
culture medium was realized at 37°C by dialysis. Aliquots of the external solution (outside the dialysis 269 
bag) were collected after various incubation times and analyzed by UV at 485 nm and confirmed that 270 
the Dox was encapsulated with an efficiency of nearly 35% (Table 1). As shown in figure 2, Dox 271 
release profiles from both types of NPs in water (Figure 2, A) and in the culture medium (Figure 2, B) 272 
are quite similar. 273 
 274 
Figure 2 275 
 276 
The release, expressed as a percentage of the total amount of encapsulated Dox, is nearly 5% after one 277 
hour of incubation. This release accelerates after the second hour to reach 40% after 6 hours of 278 
incubation in both water and culture medium. Then the release reaches a plateau around 55 to 60% 279 
from 24 to 72 hours of incubation. The fast release of Dox within the first hours is probably due to the 280 
Dox absorbed in the hydrophilic PEG corona. Indeed, Dox is known to be an amphiphilic molecule 281 
which is therefore spread from the hydrophilic corona to the surface of the hydrophobic core of the 282 
nanoparticles. However to conclude regarding the exact location of the Dox in the PEG-b-PMLABe 283 
forming NPs, it will be necessary to realize further experiments such as X-ray measurements. 284 
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Nevertheless, these results are quite encouraging because we are able to encapsulate substantial 285 
amount of this drug and the release profile is in agreement with the Dox amphiphilic nature. 286 
 287 
3.2. Grafting of fluorescein amine and cellular uptake assays 288 
Besides the use of biotin as a well-known targeting agent of cancer cells [Yang et al., 2009], we aimed 289 
at developing a versatile procedure to screen for more specific targeting agents, especially short 290 
peptides, towards  transformed hepatocytes from hepatocellular carcinoma (HCC).  291 
Our goal is to select peptides exhibiting a remarkably high tropism for the hepatocytes as targeting 292 
agents and to graft them at the surface of PMLA derivatives-based NPs in order to achieve an 293 
optimized uptake of NPs by the hepatocytes. In a first step, we wish to screen, rapidly and in a simple 294 
manner without engaging more organic chemistry, a large number of peptides which potentially show 295 
a strong hepatotropism to select the most efficient ones. For that purpose, we used the non-covalent 296 
binding of selected peptides via the strong biotin-streptavidin affinity as shown by Figure 3 [Yang et 297 
al., 2009]. 298 
 299 
Figure 3 300 
 301 
In a first step to determine whether such a molecular scaffold could allow the production of NPs and 302 
could be used for cell uptake in vitro, we have selected biotinylated cyclic RDG  (Arg-Gly-Asp- DTyr-303 
Lys-Biotin) peptide, known for interacting with integrin proteins well expressed in the liver and even 304 
more in tumors rich in extracellular matrix [Jiang et al., 2011]. This biotinylated RGD peptide has been 305 
introduced after the formation of biotinylated NPs through streptavidin interactions [Yang et al., 2009]. 306 
Moreover, in order to follow the in vitro cellular uptake of the NPs, we have synthesized fluorescein 307 
amine grafted PEG42-b-PMLABe and Biot-PEG62-b-PMLABe block copolymers. As shown by scheme 308 
1, the fluorescein amine (FA) was successfully grafted at the free carboxylic acid end of the PMLABe 309 
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block activated with N-hydroxysuccinimide (NHS) without modifying the structure of block 310 
copolymers. 311 
 312 
Scheme 1 313 
 314 
After purification by dialysis allowing the elimination of unreacted FA and low molecular weight side 315 
products, both block copolymers were characterized by 1H NMR in deuterated DMSO. The 1H NMR 316 
spectra allowed us to conclude that the structures of FA-modified block copolymers were in agreement 317 
with the expected ones and that the molecular weights of PMLABe blocks calculated from the 1H 318 
NMR spectra were identical to the ones of initial materials. 319 
Starting from a mixture of the fluorescent block copolymers and the non-fluorescent ones (50/50 wt%), 320 
we have then prepared the corresponding fluorescent NPs using the nanoprecipitation method [Huang 321 
et al., 2012; Thioune et al., 1997]. The obtained NPs were characterized by dynamic light scattering. 322 
As shown by results gathered in table 2, the presence of FA molecules at the end of the PMLABe 323 
block has no significant influence on the NP’s diameters and polydispersity indices. 324 
 325 
Table 2 326 
 327 
Biotinylated cyclic RGD peptide was then associated with NPs formed by a mixture of Biot-PEG62-b-328 
PMLABe-FA and Biot-PEG62-b-PMLABe (50/50 wt%) using streptavidin, a tetrameric protein of 56 329 
KDa purified from the bacterium Streptomyces avidinii, as an intermediate link between the biotin 330 
localized on the surface of preformed polymeric NPs and the biotinylated peptide (Figure 3). The 331 
dissociation constant (Kd) of the biotin/streptavidin complex is on the order of 10-15 mol/L, ranking 332 
among the strongest known non-covalent interactions [Yang et al., 2009]. The non-covalent binding of 333 
RGD modified fluorescent NPs was realized by first mixing the biotinylated RGD peptide with the 334 
streptavidin followed by the addition of this complex to biotinylated fluorescent NPs. The relative 335 
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amounts of block copolymers constituting the NPs, RGD peptide and streptavidin can have a 336 
significant influence on the cell capture. Therefore, different amounts of block copolymer constituting 337 
the NPs, RGD peptide and streptavidin were tested and the cell uptake was measured by fluorescent 338 
microscopy and flow cytometry (Data not shown); the best results were obtained with the following 339 
conditions: 4 µM of block copolymers under NP’s form, 4 µM of streptavidin and 8 µM of 340 
biotinylated RGD peptide. 341 
The diameter and polydispersity index of unmodified and modified NPs were measured by DLS in 342 
order to demonstrate that the addition of RGD-Biot-streptavidin construct and the dilution had no 343 
influence on the properties of the corresponding NPs. As shown by results gathered in table 3, the 344 
dilution of Biot-PEG62-b-PMLABe NPs either in PBS or in culture medium with or without serum 345 
does not have a significant influence on both the diameter and the polydispersity index values, 346 
meaning that the polymers constituting the NPs are still associated under NP’s form. 347 
 348 
Table 3 349 
 350 
The addition of the Strep-Biot-RGD construct on the biotinylated NPs has led to a moderated increase 351 
in the NPs’ diameter and polydispersity indices. For NPs resuspended either in PBS or culture medium 352 
with serum the emergence of a second peak centered at 600 nm and 970 nm, respectively, was 353 
observed. Such results indicate that addition of Strep-Biot-RGD construct does not lead to the 354 
destabilization of the NPs but rather a moderate formation of aggregates. However, such limited 355 
modifications were considered acceptable for cell uptake in vitro assays. It is important to note that 356 
RGD modified NPs were stable for at least 48 hours when stored at room temperature as shown by 357 
values of diameters and polydispersity indices unchanged (measures realized by DLS, data not shown). 358 
We then realized in vitro assays of cell captation using the human hepatoma HepaRG cell line [Laurent 359 
et al., 2010; Gripon et al., 2002]. HepaRG cells were incubated for 24 hours in the presence of 360 
biotinylated NPs modified or not with the RGD-Biot-Streptavidin construct with final concentrations 361 
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in culture media of 4 µM of block copolymers, 4 µM of streptavidin and 8 µM of RGD peptide. The 362 
cell uptake was studied by Facs and fluorescent microscopy (Figure 4).  363 
 364 
Figure 4 365 
 366 
The Facs analysis showed that the peak of fluorescence in cells incubated with the Biot-PEG62-b-367 
PMLABe-FA NPs had significantly shifted on the right compared to fluorescence in control cells 368 
incubated with non fluorescent NPs demonstrating that most of the cells contained fluorescent NPs. 369 
However, the mean of fluorescence remained low (~30 arbitrary units) for Biot-PEG62-b-PMLABe 370 
NPs and Biot-PEG62-b-PMLABe-FA NPs, respectively, compared to the mean for cells incubated with 371 
non-fluorescent NPs. The fluorescent microscopy confirmed that HepaRG cell uptake of Biot-PEG62-372 
b-PMLABe-FA NPs was very limited compared to negative control cells exposed to the non-373 
fluorescent NPs demonstrating that the biotin did not trigger a strong captation. Addition of the RGD 374 
peptide led to strong increase in the fluorescence level within HepaRG cells reaching a mean of ~1500 375 
U.A and with over 90% of positive cells (Figure 4). These data demonstrate that the addition of the 376 
RGD peptide onto NPs has considerably enhanced the cell uptake of the NPs. 377 
We then followed the time course of uptake by HepaRG cells of NPs formed by Biot-PEG62-b-378 
PMLABe-FA or Biot-RGD-Strept-Biot-PEG62-b-PMLABe-FA by flow cytometry analysis at 2, 6, 14 379 
and 24 hours of incubation. As shown by figure 5, the results of mean of fluorescence intensity 380 
indicated a very rapid uptake within the first 6 hours which continued slower until 24 hours for RGD-381 
Biot-Strept-Biot-PEG62-b-PMLABe-FA based NPs (Figure 5, red curve), while no change in the 382 
fluorescence intensity has been observed for the uptake of Biot-PEG62-b-PMLABe-FA based NPs 383 
(Figure 5, blue curve). 384 
 385 
Figure 5 386 
 387 
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Furthermore, we have evaluated the specificity of the uptake of RGD modified fluorescent NPs by 388 
HepaRG cells by comparing the efficiency of the uptake in absence or presence of an excess of free 389 
RGD peptide at a concentration of 34 µM (Figure 6). The results of fluorescence intensity measured by 390 
flow cytometry indicated that the pre-incubation of HepaRG cells with free RGD peptide before the 391 
addition of RGD modified fluorescent NPs strongly inhibited the cell uptake. Therefore, we can 392 
conclude that the presence of the RGD peptide at the NP’s surfaces is responsible for the increase in 393 
HepaRG cell uptake of NPs.  394 
 395 
Figure 6 396 
 397 
In final experiment, we compared the efficiency of the uptake of RGD modified fluorescent NPs by 398 
three different cell lines: the hepatoma HepaRG, the colon HT29 and the cervical HeLa cancer cells 399 
(Figure 7).  400 
 401 
Figure 7 402 
 403 
The three cell lines showed low levels of fluorescence following incubation with Biot-PEG62-b-404 
PMLABe-FA NPs for 24 hours demonstrating that these biotinylated NPs are poorly uptaken  by cells 405 
from different tissue origin. Importantly, the three cell types exhibited very different uptake of the 406 
RGD-Biot-Strept-Biot-PEG62- b-PMLABe-FA formed NPs. The number of positive HT29 cells is very 407 
low (< 5%) while about 90% of HeLa cells captured the RGD modified fluorescent NPs (Figure 7). 408 
However, the degree of uptake (fluorescence intensity) in HeLa cells is much lower than the one 409 
observed for HepaRG cells (Figure 7). This result suggested that the number of membrane receptors 410 
binding RGD peptide (integrin family members) on HeLa cells is sufficient to trigger the uptake of 411 
NPs by most of the cells. However, the density of these receptors onto HeLa cells might be lower than 412 
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onto HepaRG cells leading to a higher degree of NPs captation by the hepatoma cells than the HeLa 413 
cells. 414 
 415 
4. Conclusions 416 
In this study, we have demonstrated a rapid release of the Dox from PEG42-b-PMLABe and Biot-417 
PEG62-b-PMLABe NPs over the first 6 hours. However, the NPs, which are stable in water and culture 418 
medium for several days, entrapped a fraction of the drug that is slowly released over several days. 419 
Then, we characterized the cell uptake of PEG42-b-PMLABe and Biot-PEG62-b-PMLABe NPs using 420 
fluorescein amine modified polymers. We demonstrated that biotinylated NPs modified with the cyclic 421 
RGD peptide significantly increase the uptake by HepaRG cells in comparison to NPs formed by Biot-422 
PEG62-b-PMLABe-FA without peptide. We have also proved that this capture was dependent on the 423 
presence of the RGD peptide because the addition of an excess of free RGD peptide strongly inhibited 424 
the uptake. In addition, our results indicate that the RGD peptide presents a real tropism for liver cells 425 
since its uptake by HeLa and HT29 cells was much lower than the uptake by HepaRG cells. These 426 
results should be complemented by a larger study including other liver and non-hepatic cell lines as 427 
well as primary cells such as endothelial cells and normal hepatocytes. Our study also provides a proof 428 
of concept for the use of the versatile molecular scaffold presented in Figure 3 in order to screen for 429 
other short peptides targeting hepatocytes and HCC. Since we have shown that it was possible to use 430 
the streptavidin to graft a biotinylated peptide onto the biotin present at the surface of Biot-PEG62-b-431 
PMLABe based NPs, we are evaluating a number of peptides without having to engage additional 432 
chemistry. The most efficient peptides will be then grafted at the end of the hydrophilic PEG block to 433 
avoid the use of immunogenic streptavidin for further in vivo biodistribution assays. 434 
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Table 1. Characteristics of Dox-loaded NPs. 600 
NPs 
Diameter 
(nm)a 
Polydispersity index 
(Ip)a 
Zeta potential 
(mV)a 
Encapsulation efficiency 
(%)b 
PEG42-b-PMLABe 66 ± 7 0.22 - 8 ± 2 36 ± 3 
Biot-PEG62-b-PMLABe 74 ± 4 0.22 - 6 ± 1 32 ± 2 
a. Measured by DLS (Delsa™ Nano Beckman Coulter); b. Measured by UV at 485 nm. 601 
602 
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Table 2. Characteristics of fluorescent NPs measured by DLS (Delsa™ Nano Beckman Coulter). 603 
NPs Diameter (nm) Polydispersity index 
PEG42-b-PMLABe-FA + PEG42-b-PMLABe (50wt%) 64 ± 14 0.16 
Biot-PEG62-b-PMLABe-FA + Biot-PEG62-b-PMLABe (50wt%) 70 ± 13 0.22 
 604 
 605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
 613 
 614 
 615 
 616 
 617 
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Table 3. Characteristics of NPs modified or not by the strep-Biot-RGD construct measured by DLS 618 
(Delsa™ Nano Beckman Coulter). 619 
Conditions 
NPs Biot-PEG62-b-PMLABe 
NPs Biot-PEG62-b-PMLABe + 
strep-Biot-RGD 
Diameter (nm) Ip Diameter (nm) Ip 
Initial (2.5 g/L) 53 ± 12 0.17 -- -- 
Solution in PBS (0.107 g/L) 79 ± 15 0.37 208 ± 30 (a) 0.35(a) 
Solution in culture medium without serum (0.107 g/L) 78 ± 15 0.29 191 ± 21 0.28 
Solution in culture medium with serum (0.107 g/L) 106 ± 30 0.15 185 ± 30 (b) 0.23(b) 
(a). Presence of a second peak centered at 600 ± 100 nm; (b). Presence of a second peak centered at 620 
970 ± 220 nm 621 
622 
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Figure captions:  623 
Figure 1. Uses of PMLA derivatives as building blocks for the design of versatile NPs. 624 
 625 
Figure 2. Release profile of Dox in water (A) and in culture medium (B) at 37°C. 626 
 627 
Figure 3. Schematic representation of the molecular scaffold following grafting of biotinylated peptide 628 
on the biotinylated NPs via streptavidin as a bridging factor. 629 
 630 
Figure 4. Flow cytometry (right) and in situ fluorescence microscopy (left) analysis of HepaRG cells 631 
incubated with Biot-PEG62-b-PMLABe NPs, Biot-PEG62-b-PMLABe-FA NPs and RGD-Biot-Strept-632 
Biot-PEG62-b-PMLABe-FA NPs. For Facs analysis, size (FSC-H) and granularity (SSC-H) were 633 
visualized to select the R1 gate corresponding to living cells. Detection on fluorescent cells in the R1 634 
gate was performed using the FL1-H channel: negative cells incubated with Biot-PEG62-b-PMLABe 635 
NPs were set in the M1 window and positive cells were detected in the M2 window. For cells 636 
incubated with Biot-PEG62-b-PMLABe-FA and RGD-Biot-Strept-Biot-PEG62-b-PMLABe-FA NPs () 637 
50 and () 90% of cells were fluorescent, respectively; white bar : 50 µm. 638 
 639 
Figure 5. Time course of the uptake of NPs by HepaRG cells. Red curve: RGD-Biot-Strept-Biot-640 
PEG62-b-PMLABe-FA NPs; Blue curve: Biot-PEG62-b-PMLABe-FA NPs; white bar : 50 µm. 641 
 642 
Figure 6. Captation of fluorescent nanoparticles (24 hour incubation) by HepaRG cells in absence or in 643 
presence of free RGD peptide; Flow cytometry (Left) and fluorescence microscopy (Rigth) analyses 644 
with Biot-PEG62-b-PMLABe-FA NPs, RGD-Biot-Strept-Biot-PEG62-b-PMLABe-FA NPs and RGD-645 
Biot-Strept-Biot-PEG62-b-PMLABe-FA NPs + 34 µM of free RGD peptide. Bottom chart: Mean of 646 
fluorescence under the various tested conditions. 647 
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Figure 7. Flow cytometry measurements of fluorescence in HepaRG, HT29 and HeLa cells incubated 648 
with Biot-PEG62-b-PMLABe-FA or RGD-Biot-Strept-Biot-PEG62-b-PMLABe-FA formed NPs for 24 649 
hours. Left chart: Number of positive cells; right chart: Mean of fluorescence. 650 
651 
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Figure 3.  658 
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Figure 4. 666 
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Figure 5.  669 
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Figure 6.  678 
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Figure 7. 704 
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Scheme captions  707 
 708 
Scheme 1. Synthetic route to FA grafted PEG42-b-PMLABe and Biot-PEG62-b-PMLABe. 709 
710 
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Scheme 1. 711 
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